Injectable borax-loaded alginate hydrogels reduce muscle atrophy, modulate inflammation, and promote neuroprotection in the SOD1G93A mouse model of ALS through mechanisms involving IGF–Akt–mTOR signaling

Rodriguez-Romano, Ana ; Gonzalez-Valdivieso, Juan ; Moreno-Martinez, Laura (Universidad de Zaragoza) ; Vázquez Costa, Juan Francisco ; Osta, Rosario (Universidad de Zaragoza) ; Rico, Patricia

Resumen: Amyotrophic Lateral Sclerosis (ALS) is a prevalent condition characterized by motor neuron loss and skeletal muscle paralysis. Despite being associated to mutations in over 40 genes, its etiology remains elusive without a cure or effective treatment. ALS, historically considered a motor neuron disease, is defined today as a multisystem disorder involving non-neuronal cell types, including early muscle pathology independent of motor neuron degeneration (dying back hypothesis), thus skeletal muscle actively contributes to disease pathology, making it a viable therapeutic target for ALS.
Our previous research has shown that boron transporter NaBC1 (encoded by the SLC4A11 gene), after activation co-localizes with integrins and growth factor receptors synergistically enhancing muscle repair. Here we investigate the effects of injectable alginate-based hydrogels for controlled local borax release in Amyotrophic Lateral Sclerosis muscle. Treated mice showed improved motor function, prolonged survival, and activation of essential muscle metabolic pathways, leading to enhanced muscle repair and reduced atrophy and inflammation. Interestingly, local muscle repair activation provided retrograde neuroprotection by preserving motor neurons and reducing neuro-inflammation. This study highlights the role of muscle tissue in ALS pathology, supporting its targeting with NaBC1-based therapies for muscle regeneration.

Idioma: Inglés

DOI: 10.1016/j.ijbiomac.2025.145645

Año: 2025

Publicado en: International journal of biological macromolecules 319 (2025), 145645 [16 pp.]
ISSN: 0141-8130

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CB06-01-1026
Financiación: info:eu-repo/grantAgreement/ES/AEI/MICNN/PID2021-126012OB-I00

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Genética (Dpto. Anatom.,Embri.Genét.Ani.)
Área (Departamento): Área Farmacología (Dpto. Farmac.Fisiol.y Med.L.F.)